FDA Updates Rules for Safe Medical Gas Production
Published Date: 12/1/2025
Notice
Summary
The FDA just dropped a new draft guide to help medical gas makers follow updated safety and quality rules starting December 18, 2025. This affects anyone making gases for humans or animals, aiming to keep products pure and safe while cutting down on red tape. If you’re in the biz, get ready to review and comment by January 30, 2026, so your voice shapes the final rules!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Medical-gas CGMPs take effect
If you manufacture medical gases for people or animals, new medical-gas-specific good manufacturing practice rules take effect on December 18, 2025, and those rules (part 213) replace the general drug CGMP rules in parts 210 and 211. Conforming amendments for combination products became effective February 2, 2026.
Guidance clarifies key compliance areas
FDA issued a draft guidance (revising the June 2017 draft) to explain how to comply with the new medical-gas CGMPs. The draft guidance includes recommendations and clarifications on ensuring supplier reliability, protecting against container closure leaks, cleaning and equipment maintenance, preventing labeling and product mix-ups, when to do stability or expiration testing, and handling returned or salvaged medical gases.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
The FDA is officially putting the hyperoxia monitoring device that works with pulse oximeters into a safer, easier-to-manage category called Class II. This change, effective October 6, 2026, means the device will have special safety rules but fewer regulatory hurdles, helping patients get access to this cool tech faster. Medical device makers and healthcare providers will feel the impact, with smoother approval processes and no big new costs expected.
Previous / Next Documents
Previous: 2025-21688, Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Previously Approved Collection Application/Permit To Import Firearms, Ammunition, and Defense Articles-ATF Form 5330.3A (Form 6, Part I)
The ATF is updating the form used to apply for permits to import firearms, ammo, and defense gear. This affects importers who’ll see some changes to the paperwork, aiming to make it clearer and easier to handle. Comments on the update are open until January 30, 2026, with no new fees expected.
Next: 2025-21690, Agency Information Collection Activities: Submission for OMB Review; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your feedback on their plan to collect some information from the public. This is a routine check to make sure the questions they ask are useful and not too much work. If you have thoughts, you’ve got until December 31, 2025, to share them—no cost, just your voice!